Tazobactam

Tazobactam is a sulfone-based suicide inhibitor of beta-lactamase enzymes, structurally related to penicillin. It works by irreversibly binding to the active site of beta-lactamases (particularly class A enzymes like TEM, SHV, and some extended-spectrum beta-lactamases), preventing them from hydrolyzing the beta-lactam ring of co-administered antibiotics. It is most commonly paired with piperacillin (Zosyn/Piperacillin-tazobactam) to broaden coverage against beta-lactamase-producing organisms including Pseudomonas aeruginosa, many Enterobacteriaceae, and anaerobes like Bacteroides fragilis. This combination is a mainstay for empiric treatment of serious nosocomial infections, intra-abdominal infections, febrile neutropenia, and hospital-acquired/ventilator-associated pneumonia. Tazobactam does not restore activity against metallo-beta-lactamases, AmpC-type enzymes with constitutive hyperproduction, or carbapenemases (e.g., KPC). Clinically important: piperacillin-tazobactam can cause false-positive galactomannan assay results (used for Aspergillus detection), and dosing requires renal adjustment due to renal excretion. Adverse effects mirror penicillin-class drugs: hypersensitivity reactions, GI upset, and rare interstitial nephritis. It is often tested in combination with piperacillin for spectrum coverage questions, mechanism of beta-lactamase inhibition, and drug interactions/false lab results on USMLE.